UNEEKE Technologies Ltd. – Revolutionizing Healthcare with Nature-Inspired Solutions to Combat ALL Pathogens – Bacterial, Viral, Fungal and ABR - thereby Redefining Treatment Strategies for Infections

In the unfolding saga of human health, there has been a significant shift—from an era dominated by infectious diseases to the rise of non-communicable illnesses. However, the tides are turning once again, with infectious diseases resurging at an alarming rate, prompting an urgent call for innovative responses. Amid this race against time, the world grapples with a dual menace: a compromised immune system resulting from modern dietary changes and the formidable specter of Antibiotic Resistance (ABR), giving rise to resilient ‘superbugs’.

In response to this urgency, UNEEKE Technologies Ltd. (www.uneeketechnologies.com) represents a monumental leap forward in the ongoing battle against pathogens. It promises a safer, more sustainable approach to infection control, elevating the standards of healthcare for a healthier, more resilient future.

Richard Stead, CEO of UNEEKE Technologies Ltd., spoke extensively with CIO Bulletin about how he and his company are actively involved in the development of a groundbreaking class of drugs, aiming to combat infections and eliminate ALL pathogens effectively.

Interview Highlights

Q. What inspired the founding of UNEEKE Technologies Ltd., and how has the journey been so far?

In the past, I have, at times, held the position as the leading supplier in the UK for MSG, Aspartame, and numerous other synthetic food additives. However, these substances, after relatively short periods, gained negative connotations, being linked to potential harm to human health. It is crucial to recognize that WE ARE NOT WHAT WE EAT: WE ARE WHAT WE ABSORB.

In approximately 2016, I made the determination that our industry must strive for improvement. Observing the rising incidence of mental and physical health problems in the developed Western world, I noted that many solutions provided by pharmaceutical suppliers were not as effective as in the recent past. It has been nearly 100 years since the introduction of antibiotics, yet the drugs designed to combat infections have started losing their efficacy. There had to be better ways to serve people, and it is indeed time to explore alternatives.

Q. What products or services does UNEEKE Technologies Ltd. offer, and how do they address specific market needs?

I offer products based on Nature’s technologies to combat pathogens that cause serious health problems in both humans and animals. When referring to pathogens, I mean ALL bacteria, viruses, fungal and resistant species. I firmly believe that NATURE HAS THE ANSWER: CHEMISTRY IS THE KEY. Our technology is rooted in the body’s primary mechanisms to eliminate pathogens causing problems.

Q. How does UNEEKE Technologies Ltd. approach rebalancing and modulating the microbiome to promote better health and well-being?

By analyzing an individual’s gut microbiome composition, we can determine the root cause of their health issues and devise a plan to restore balance to their gut microbiome. It has been evident for many years that numerous health conditions stem from an imbalanced gut, notably impacting mental health issues such as depression, Bipolar disorder, AUTISM, and recently, reports have linked gut bacteria to Alzheimer’s.

Techniques for identifying gut bacterial composition have advanced significantly in the past decade. With these advancements, I demonstrate how my molecule addresses dysbiosis. Once pathogens are eliminated, we can then work on rejuvenating the gut to achieve its optimal balance for that individual. Interestingly, no two guts possess the same bacterial balance, not even among identical twins.

I collaborate closely with labs equipped with exceptional techniques and expertise to measure and analyze the gut microbiome. Together, we outline steps to achieve the ideal gut balance tailored to each individual’s physical and mental well-being. We advise caution before consuming probiotics, not because they are inherently harmful, but to select those specifically beneficial for one’s gut. Gut analysis stands as an essential step in this process. Excessive good bacteria can potentially lead to dysbiosis due to an imbalance, resulting in adverse health effects.

The remarkable aspect of my technology, apart from its effectiveness against pathogens, lies in its non-invasive nature towards commensal (friendly) bacterial species. Additionally, it causes no harm to human or animal cells or DNA.

Q. Given the crisis of resistance to established interventions, how will UNEEKE Technologies Ltd. contribute to overcoming these pathogens, including viruses and fungi that have developed resistance to the last lines of medicines. Can you elaborate on the specifics of UNEEKE Technologies Ltd.’s PostABR^® technology and how it differs from traditional antibiotics in its mode of action?

In humans, the use of antibiotics has extended over a prolonged period. This extended duration has led to an excess of antibiotics, providing pathogenic organisms with the time needed to develop survival mechanisms. Subsequently, these adaptations have been shared and spread to other species of bacteria, including species of viral and fungal pathogens.

In contrast, Nature’s methods are characterized by a shorter time span. They involve the use of molecules with a limited lifespan that naturally break down, preventing pathogens from learning to thrive in the presence of the antimicrobial molecule. This approach disrupts the pathogen’s ability to adapt and develop resistance over time.

Q. What can you tell us about the team behind UNEEKE Technologies Ltd.?

The Team is me. With a background in Chemistry, I recognized the necessary steps and meticulously executed my plans. Utilizing both my personal facilities and external laboratories equipped with skilled personnel, I directed experiments and research activities. In under a decade, I acquired the knowledge to mimic nature’s methods in combating incoming pathogens.

The breakthrough lies in a single small molecule that mirrors nature’s approach to neutralizing pathogens. This molecule targets a specific grouping on the pathogen’s cell wall, rendering the pathogen  cell non-functional and effectively halting the infection. Named HYPOTHIOCYANITE (OSCN-), the molecule boasts a remarkably low molecular weight of just 74. In contrast, many antibiotics, antifungals, and antivirals have molecular weights in the thousands. This disparity underscores the efficiency and precision of this innovative technology.

UNEEKE Technologies Ltd. exhibits remarkable efficacy across various parameters, with a total score of 19 out of 20. Overall, the company, with its state-of-the-art products, proves it combats pathogens with an iron fist.

Q. What are the company’s goals and aspirations for the future, especially considering the trends in the industry?

There exists a profound urgency within the medical community, encompassing governments and insurers, to seek alternatives to antibiotics, antifungals, and antivirals. My primary goal is to secure adequate investment to expedite the introduction of this technology into the market. PATHOGENS ARE EVERYWHERE, and they pose challenges across various facets of our lives, spanning agriculture, food processing, and even the air we breathe. Therefore, it’s crucial that this technology extends beyond the realm of healthcare.

To cater to these diverse applications, I’ve developed manufacturing processes, delivery techniques, and specialized equipment. These innovations enable the technology to function effectively wherever it is required. Notably, my technology has proven effective in eliminating airborne pathogens like COVID, thereby ensuring safer environments for activities such as attending theaters or undergoing surgery in hospital operating theaters. This holds the potential to decrease the escalating cases of Surgical Site Infections (SSIs).

Q. What message would you like to convey to the readers of CIO Bulletin and your existing clients?

Considering the alarming prevalence of Alzheimer’s, now identified as the leading cause of mortality among US seniors, I am hopeful that my investors will support and encourage the allocation of their funds towards further research on the gut health of Alzheimer’s sufferers. My goal is to develop comprehensive protocols aimed at finding a cure for Alzheimer’s.

Furthermore, with significant progress in identifying the pathogens associated with Autism, I am confident in the potential success of my plans to eradicate Alzheimer’s.

“Within the confines of a single molecule, HYPOTHIOCYANITE (OSCN-) mirrors nature’s mastery in neutralizing pathogens. With its minuscule weight of 74, it zeroes in on a pathogen’s cell wall, disabling it with precision—an innovation that highlights unparalleled efficiency in combating infections.”

For more information, to contact Richard or indicate your interest in investing with him, please go to www.uneeketechnologies.com and follow the clicks or call +44 7850596172. He always replies.